Adjudin (known as AF-2364) was developed as a male contraceptive drug, which induces reversible germ cell loss from the seminiferous epithelium by disrupting cell adhesion function between Sertoli and germ cells, in particular, elongating/elongate/round spermatids and spermatocytes but not spermatogonia. This drug was in phase II clinical trial for human. In addition was discovered, that adjudin could trigger mitochondrial dysfunction in cancer cells, apparently affecting the mitochondrial mass, inducing the loss of mitochondrial membrane potential and reducing cellular ATP levels and thus could be a potential drug for cancer therapy.